Table 1 Clinicopathological features of CASC patients in our cohort

Age [years]

53[5.5]

Male gender

8(72.7)

Tumor stage

I

1(9.1)

II

1(9.1)

III

4(36.4)

IV

5(45.5)

Tumor depth

T1

1(9.1)

T2

1(9.1)

T3

3(27.3)

T4

6(54.5)

Tumor locations

ileocecal

1(9.1)

Ascending colon

2(18.2)

Transverse colon

1(9.1)

Descending colon

1(9.1)

Sigmoid colon

2(18.2)

Rectum

3(27.3)

Multi-site (sigmoid colon + cecum)

1(9.1)

Ki-67 (%)

40% [15.5%]

Tumor diameter (cm)

6.0 [3.5]

Metastatic sites

Lung

1(9.1)

Liver

1(9.1)

Peritoneal

2(18.2)

Ureter

1(9.1)

Lymph node

7(63.6)

Neoadjuvant therapy

1(9.1)

Adjuvant therapy

Chemotherapy

3(27.3)

Immunotherapy

1(9.1)

Radiotherapy

1(9.1)

Tumor progression

7(63.6)

Local recurrence

4(36.4)

Distant metastasis

Liver

1(9.1)

Ureter

1(9.1)